Clinical Trials

1,000 enrolled

Breast Neoplasms

NCT06312176 2026-03-13

MK-2870-010

1,200 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT06841354 2026-03-13

TroFuse-011

1,000 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT06953999 2026-03-04

A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer

999 enrolled

Pancreatic Neoplasms

NCT06447662 2026-02-25

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Phase 1 Recruiting

330 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06731907 2026-02-18

MK-3475-01G

Phase 2 Recruiting

90 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07281976 2026-02-12

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

220 enrolled

Triple Negative Breast Neoplasms

NCT07280377 2025-12-12

GOBLET

122 enrolled

Anal Cancer Metastatic

NCT03257033 2025-11-14

TIGeR-PaC

190 enrolled

Locally Advanced Pancreatic Cancer

NCT06953323 2025-08-13

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

86 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07096869 2025-07-31

Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients

Phase 1 Recruiting

28 enrolled

Bioequivalence

NCT04894643 2025-05-08

PARC

Phase NA Recruiting

10 enrolled

Pancreatic Neoplasms

NCT05827796 2025-04-30

IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

70 enrolled

Pancreatic Neoplasms

NCT05431270 2025-01-31

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05254171 2024-11-06

ASPIRE

Phase 2/3 Recruiting

600 enrolled